Vireo Growth (VREOF) details Eaze merger, 2025 pro forma revenue of $409.9M and $94.9M loss
Rhea-AI Filing Summary
Vireo Growth Inc. filed an amended report to add full-year 2025 financials for its newly acquired subsidiary Eaze, Inc. and pro forma results for the combined company. Eaze generated $141.1 million in 2025 sales and recorded a net loss of $24.1 million, with total assets of $101.8 million and stockholders’ equity of $18.8 million.
The amendment also provides pro forma 2025 figures as if the Eaze merger had been in place all year, showing combined revenue of $409.9 million and a net loss of $94.9 million. Vireo issued about 90.4 million subordinate voting shares, valued at an estimated $34.3 million, as closing consideration. Eaze operates cannabis cultivation, manufacturing and retail businesses in Colorado, California and Florida and is affected by U.S. tax rules such as Section 280E and evolving federal cannabis regulation, including a recent move to reclassify certain marijuana-related products to Schedule III.
Positive
- None.
Negative
- None.
Insights
Amended filing quantifies the scale and losses of the Eaze acquisition and its impact on Vireo’s pro forma results.
The amendment mainly adds audited 2025 financials for Eaze and detailed pro forma statements. Eaze posted $141.1M of sales but a net loss of $24.1M, with sizable lease and tax-related liabilities, which shape the combined balance sheet.
On a pro forma basis, Vireo’s 2025 revenue rises to $409.9M, with a combined net loss of $94.9M. Merger consideration is estimated at $34.3M, paid in 90.4M subordinate voting shares, and preliminary purchase accounting records $6.46M of goodwill. Management currently assigns zero value to the EBITDA-based earnout, which could change as performance and valuations are finalized.
The notes also highlight exposure to cannabis-specific risks, including an uncertain tax position of $11.8M at Eaze and federal tax limits under IRC Section 280E. A subsequent federal move to reclassify certain marijuana products to Schedule III is disclosed as a potential future driver of tax and regulatory changes, though no quantitative impact is yet recorded.


